Department of Otolaryngology, Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Immunotherapy. 2022 Jun;14(8):655-662. doi: 10.2217/imt-2021-0310. Epub 2022 May 4.
Chronic rhinosinusitis with nasal polyposis is a heterogenous disease with complex underlying pathophysiologic mechanisms. Biologics have been proven to be an effective add-on therapeutic option in severe and/or refractory cases. Currently, dupilumab, omalizumab and mepolizumab have phase III data to support their use in these patients and have received approval from the United States Food and Drug Administration specifically for the treatment of nasal polyposis. Each of these biologics has shown its ability to reduce nasal polyp size and improve nasal congestion/obstruction and sense of smell, but additional research is needed to directly compare the efficacy and safety of the different biologic agents for different nasal polyposis endotypes.
伴有鼻息肉的慢性鼻-鼻窦炎是一种具有复杂潜在病理生理机制的异质性疾病。生物制剂已被证明是严重和/或难治性病例的有效附加治疗选择。目前，度普利尤单抗、奥马珠单抗和美泊利珠单抗有 III 期数据支持其在这些患者中的应用，并已获得美国食品和药物管理局的批准，专门用于治疗鼻息肉。这些生物制剂都显示出了减少鼻息肉大小、改善鼻塞/阻塞和嗅觉的能力，但需要进一步的研究来直接比较不同生物制剂治疗不同鼻息肉表型的疗效和安全性。
